Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell Lines
Open Access
- 9 October 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (10), e7373
- https://doi.org/10.1371/journal.pone.0007373
Abstract
The mTOR inhibitor rapamycin has anti-tumor activity across a variety of human cancers, including hepatocellular carcinoma. However, resistance to its growth inhibitory effects is common. We hypothesized that hepatic cell lines with varying rapamycin responsiveness would show common characteristics accounting for resistance to the drug. We profiled a total of 13 cell lines for rapamycin-induced growth inhibition. The non-tumorigenic rat liver epithelial cell line WB-F344 was highly sensitive while the tumorigenic WB311 cell line, originally derived from the WB-F344 line, was highly resistant. The other 11 cell lines showed a wide range of sensitivities. Rapamycin induced inhibition of cyclin E–dependent kinase activity in some cell lines, but the ability to do so did not correlate with sensitivity. Inhibition of cyclin E–dependent kinase activity was related to incorporation of p27Kip1 into cyclin E–containing complexes in some but not all cell lines. Similarly, sensitivity of global protein synthesis to rapamycin did not correlate with its anti-proliferative effect. However, rapamycin potently inhibited phosphorylation of two key substrates, ribosomal protein S6 and 4E-BP1, in all cases, indicating that the locus of rapamycin resistance was downstream from inhibition of mTOR Complex 1. Microarray analysis did not disclose a unifying mechanism for rapamycin resistance, although the glycolytic pathway was downregulated in all four cell lines studied. We conclude that the mechanisms of rapamycin resistance in hepatic cells involve alterations of signaling downstream from mTOR and that the mechanisms are highly heterogeneous, thus predicting that maintaining or promoting sensitivity will be highly challenging.This publication has 48 references indexed in Scilit:
- mTORβ Splicing Isoform Promotes Cell Proliferation and TumorigenesisJournal of Biological Chemistry, 2009
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1Journal of Biological Chemistry, 2009
- Pivotal Role of mTOR Signaling in Hepatocellular CarcinomaGastroenterology, 2008
- Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2008
- Reconstructing networks of pathways via significance analysis of their intersectionsBMC Bioinformatics, 2008
- Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerasesOncogene, 2006
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- D-type cyclins and G1 progression during liver development in the ratBiochemical and Biophysical Research Communications, 2005
- Gene Expression Omnibus: NCBI gene expression and hybridization array data repositoryNucleic Acids Research, 2002
- Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progressionCell, 1993